Use of nicotinic analogs for treatment of degenerative...

Details Use of nicotinic analogs for treatment of degenerative... Use of nicotinic analogs for treatment of degenerative...

C - Chemistry, Metallurgy

07

D

C07D 401/04 (2006.01) A61K 31/44 (2006.01) A61K 31/445 (2006.01)

Patent

CA 2105071

A novel pharmaceutical composition for use as an anti-neurodegenerative agent, comprising anabaseine, DMAB-anabaseine or anabasine in combination with a pharmaceutically acceptable carrier, the anabaseine having the general chemical structure: (see formula I) and the anabaseine, DMAB-anabaseine or anabasine also known by the following respective chemical formulae: 2-(3-pyridyl)-3,4,5,6-tetrahydropyridine, 3-[p- (dimethylamino) benzylidene]-3,4,5,6-tetrahydro-2,3'-bypyridine, and 2-(3-pyridyl) piperidine. A novel method of making an anabaseine-based pharmaceutical composition is also disclosed.

Affiliated with

Also associated with

Rating

Use of nicotinic analogs for treatment of degenerative... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of nicotinic analogs for treatment of degenerative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nicotinic analogs for treatment of degenerative... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2021478